VERMONT IMMUNOBIOLOIGY/ INFECTIOUS DISEASES CENTER

佛蒙特州免疫生物学/传染病中心

• 批准号: 8360768
• 负责人: Ralph C Budd
• 金额: $ 89.31万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-20 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360768
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Area; Award; Bioinformatics; Categories; Centers of Research Excellence; Chronic; Communicable Diseases; Educational workshop; Extramural Activities; Faculty; Funding; Genome; Grant; Health; Immune response; Immunology; Infection; Infectious Disease Immunology; Inflammation; Joints; Laboratories; Malignant Neoplasms; Medicine; Mentors; National Center for Research Resources; Pathogenesis; Phase; Pilot Projects; Positioning Attribute; Principal Investigator; Proteomics; Publications; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Resources; Scientist; Series; Source; Technology; Thinking; United States National Institutes of Health; Universities; Vermont; Writing; biosafety level 3 facility; career development; college; cost; microbial; multidisciplinary; novel vaccines; planetary Atmosphere; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Regarding AIDS DESCRIPTION (provided by applicant): This application proposes the Phase II COBRE continuation of the Vermont Center for Immunology and Infectious Diseases (VCIID) at the University of Vermont (UVM). During the Phase I COBRE period we created a multidisciplinary group of scientists and clinicians undertaking collaborative research in microbial pathogenesis and the immune response to infections. The keystone of Phase I was to achieve scientific excellence while building a critical mass of investigators in a vibrant and rigorous atmosphere. A significant component of this was the mentoring of 5 original junior faculty, all of whom obtained extramural funding, had numerous publications and awards, and 4 of 5 have been promoted. We also recruited 5 additional junior faculty in the final two years of Phase I. Already 4 of these 5 new faculty have obtained some extramural funding. In addition, the VCIID-COBRE provided support for cores in Genome Technologies/Bioinformatics, Proteomics, a seminar series of outside experts, a weekly Research-in- Progress forum, retreats, pilot project funding, and workshops on scientific issues, grant writing, and career development. As a result of these programs the VCIID grew during Phase I from 9 founding faculty to 21 faculty in 8 departments in 4 colleges, with 213 publications (49 from junior faculty), $47,694,003 in funding, without the COBRE ($8,818,374 from junior faculty), and recognition by the UVM College of Medicine as one of the five Centers of Excellence. During Phase II we will continue several of the above successful programs but modify them toward directing the faculty toward becoming a highly interactive group in a mature Center with collaborative grants and sustainability. The new 5 junior faculty will continue their projects for 1-4 additional years. Two senior faculty we be recruited to fill gaps in our intellectual repertoire, one in mucosal immunology to enhance our new Vaccine Trials Center, and the second in chronic infection/inflammation-induced cancer to broaden our thinking to the implications of chronic infectious conditions. Cores will be continued in Genome Technologies/Bioinformatics and Proteomics, with the addition of a new BSL3 facility core to accommodate the growing needs of VCIID investigators desiring to study BSL3 agents. Also in this area, we will form a unique partnership among the VCIID, UVM, and the Vermont Department of Health in which the State will build a new Department of Health laboratory building on the UVM campus attached to our research building containing the BSL3 facility. This will provide space for an expanded joint BSL3 facility to include animal and select agent use. These endeavors will position us to be competitive for new POI and U19 category grants.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 关于艾滋病 描述（由申请人提供）：本申请提出佛蒙特大学 (UVM) 佛蒙特免疫学和传染病中心 (VCIID) 的 II 期 COBRE 延续。在第一阶段 COBRE 期间，我们创建了一个由科学家和临床医生组成的多学科小组，开展微生物发病机制和感染免疫反应方面的合作研究。第一阶段的重点是实现科学卓越，同时在充满活力和严谨的氛围中培养足够数量的研究人员。其中一个重要组成部分是对 5 名原始初级教师的指导，他们都获得了校外资助，发表了大量出版物并获得奖项，其中 5 名教师中有 4 名获得晋升。我们还在第一阶段的最后两年招募了 5 名初级教师。这 5 名新教师中已有 4 名获得了一些校外资助。此外，VCIID-COBRE 还为基因组技术/生物信息学、蛋白质组学、外部专家研讨会系列、每周一次的研究进展论坛、务虚会、试点项目资助以及有关科学问题、资助写作和职业发展的研讨会提供支持。由于这些计划的实施，VCIID 在第一阶段从 9 名创始教师发展到 4 个学院 8 个系的 21 名教师，发表了 213 篇出版物（其中 49 篇来自初级教师），在没有 COBRE 的情况下获得 47,694,003 美元的资助（8,818,374 美元来自初级教师），并被 UVM 医学院认可为五个卓越中心之一。在第二阶段，我们将继续上述几个成功的项目，但对其进行修改，以指导教师成为一个成熟中心中的高度互动的团体，并提供协作资助和可持续性。新的 5 名初级教师将继续他们的项目 1-4 年。我们招募了两名高级教员来填补我们知识库的空白，其中一名在粘膜免疫学领域，以加强我们新的疫苗试验中心，第二名在慢性感染/炎症诱发的癌症领域，以拓宽我们对慢性感染性疾病影响的思考。基因组技术/生物信息学和蛋白质组学的核心将继续存在，并增加一个新的 BSL3 设施核心，以满足希望研究 BSL3 药物的 VCIID 研究人员不断增长的需求。同样在这一领域，我们将在 VCIID、UVM 和佛蒙特州卫生部之间建立独特的合作伙伴关系，佛蒙特州将在 UVM 校园内建造一座新的卫生部实验室大楼，毗邻我们包含 BSL3 设施的研究大楼。这将为扩大 BSL3 联合设施提供空间，以包括动物和精选药剂的使用。这些努力将使我们在新的 POI 和 U19 类别资助方面具有竞争力。